Doms № 1 -2022

Doms № 1 -2022 (73-83 p)

Simplifying complex insulin regimens while preserving good glycemic control in type 2 diabetes
Zoltán Taybani, Balázs Bótyik, Mónika Katkó, András Gyimesi,Tamás Várkonyi – 73-83

Introduction. Type 2 diabetic patients suffering from severe hyperglycemia are often assigned a regimen involving multiple daily injections (MDI) of insulin. If the glucose toxicity resolves, the regimen can potentially be simplified, but there are no guidelines for this, and many patients are left on the MDI regimen. We aimed to prospectively examine the safety and efficacy of switching from MDI to once-daily IDegLira, a fixed-ratio combination of insulin degludec and liraglutide, in relatively well controlled (HbA1c ≤ 7.5 %) subjects with type 2 diabetes on a low total daily insulin dose (TDD).
Methods. 62 adults with type 2 diabetes (baseline age 64.06 ± 10.24 years, HbA1c 6.42 ± 0.68%, BMI 33.53 ± 6.90 kg/m2, body weight 93.81±19.26 kg, TDD 43.31±10.99 IU/day, insulin requirement 0.47±0.13 IU/kg, duration of diabetes 10.84 ± 7.50 years, mean ± SD) treated with MDI ± metformin were enrolled in our study. Previous insulins were stopped and once-daily IDegLira was started. IDegLira was titrated by the patients to achieve a self-measured pre-breakfast blood glucose concentration of<6 mmol/L.
Results. After a mean follow-up period of 99.2 days, mean HbA1c had decreased by 0.30% to 6.12±0.65% (p<0.0001), body weight had decreased by 3.11 kg to 90.70±19.12 kg (p<0.0001), and BMI had reduced to 32.39 ± 6.71 kg/m2 (p < 0.0001). After 3 months of treatment, the mean dose of IDegLira was 20.76 ± 6.60 units and the mean insulin requirement had decreased to 0.23 ± 0.08 IU/kg. IDegLira ± metformin combination therapy was found to be safe and generally well tolerated. During the month before the baseline visit, 28 patients (45 %) had at least one episode of documented or symptomatic hypoglycemia, while only 6 (9.67 %) patients reported a total of 13 documented episodes during the follow-up.
Conclusion. In everyday clinical practice, switching from low-dose MDI to IDegLira in patients with well- controlled type 2 diabetes is safe, may result in weight loss and similar or better glycemic control, and substantially reduces the insulin requirement. Simplifying complex treatment regimens decreases treatment burden and may improve adherence to therapy.

Keywords: Deintensification, IDegLira, Overtreatment, Simplification, Type 2 diabetes.

Clinical Trial Number: NCT04020445.

  1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.

  2. Jermendy G, Gaa l Z, Gero} L, Hidvegi T, et al. Clinical practice guideline—diagnosis, antihyperglycaemic treatment and care of patients with diabetes in adulthood. Diabetol Hungar. 2017;25(1):3–77.

  3. American Diabetes Association. 11. Older adults: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl. 1):S119–25.

  4. Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. JAMA. 1998;280(11):1000–5.

  5. Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015;175(3):356–62.

  6. Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM. Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med. 2014;174(2):259–68.

  7. McAlister FA, Youngson E, Eurich DT. Treated glycosylated hemoglobin levels in individuals with diabetes mellitus vary little by health status: a retrospective cohort study. Medicine (Baltimore). 2016;95(24):e3894.

  8. Sussman JB, Kerr EA, Saini SD, et al. Rates of deintensification of blood pressure and glycemic medication treat- ment based on levels of control and life expectancy in older patients with diabetes mellitus. JAMA Intern Med. 2015;175(12):1942–9.

  9. McAlister FA, Youngson E, Eurich DT. Treatment deintensification is uncommon in adults with type 2 diabetes mellitus: a retrospective cohort study. Circ Cardiovasc Qual Outcomes. 2017;10(4):e003514.

  10. Maciejewski ML, Mi X, Sussan J, et al. Overtreatment and deintensification of diabetic therapy among Medicare beneficiaries. J Gen Intern Med. 2018;33(1):34–41.

  11. Munshi MN, Slyne C, Segal AR, Saul N, Lyons C, Weinger K. Simplification of insulin regimen in older adults and risk of hypoglycemia. JAMA Intern Med. 2016;176(7):1023–5.

  12. Abdelhafiz AH, Sinclair AJ. Deintensification of hypoglycaemic medications—use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes. J Diabetes Complications. 2018;32(4):444–50.

  13. Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care. 2018;41(5):1009–16.
  14. Gough SC, Jain R, Woo VC. Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab. 2016;11(1):7–19.
  15. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl. 1):S90–102.
  16. Thorpe CT, Gellad WF, Good CB, et al. Tight glycemic con- trol and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care. 2015;38(4):588–95.
  17. Khunti K, Davies MJ. Clinical inertia versus overtreatment in glycaemic management. Lancet Diabetes Endo- crinol. 2018;6(4):266–8. https://doi. org/10.1016/S2213- 8587(17)30339-X.
  18. Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat- to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885–93.
  19. Gough SC, Bode BW, Woo VC, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab. 2015;17(10):965–73.
  20. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
  21. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–32.
  22. Leighton E, Sainsbury CA, Jones GC. A practical review of C- peptide testing in diabetes. Diabetes Ther. 2017;8(3):475–87. 23. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents. Diabetes

    Care. 2008;31(1):20–5.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52-week,

    multinational, open-label, parallel-group, noninferiority, treat- to-target trial comparing insulin detemir with insulin glargine in a basal–bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11): 1976–87.